Literature DB >> 7889380

Compliance with an allergen immunotherapy regime.

D Tinkelman1, F Smith, W Q Cole, H J Silk.   

Abstract

BACKGROUND: Compliance with an allergy immunotherapy regimen is obviously the difference between a potentially successful or unsuccessful outcome.
OBJECTIVE: The purpose of this study was to assess retrospectively compliance of patients receiving immunotherapy in a private allergy practice.
METHODS: The study evaluated retrospectively patient compliance with prescribed allergy injections for a private practice in Atlanta, Georgia. Patients who ordered allergy extract material for their injection immunotherapy program during an 18-month period served as the index population for this study. For the purposes of this study, noncompliance was defined as stopping the allergy injection program without the approval of the prescribing physician. Part of this investigation was to determine whether there were compliance differences between those who received their allergy injections within the confines of the clinic and those who received their injections at outside physician offices. A 12-month period of review was considered adequate to monitor compliance because of the 12-month expiration date placed on the allergy extracts.
RESULTS: There was a noncompliance rate of 10: 77% for those who received their injections within the clinic. This contrasted with the noncompliance rate in the remote population of 34.82%. The difference between these two groups was statistically significant (P < .01). There were no statistical differences with respect to sex or diagnostic category. Significant differences were found between age groups in those receiving injections within or outside the clinic.
CONCLUSIONS: There is a much higher rate of noncompliance in those who receive their injections in facilities outside the allergist's office. This suggests that to ensure better compliance either individuals should either be encouraged to receive their injections at the allergist's office, or better communications should be established between the referring allergist and the nonallergy physicians who are administering the injections.

Entities:  

Mesh:

Year:  1995        PMID: 7889380

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  7 in total

1.  [Persistence and frequency of prescriptions of subcutaneous allergen-specific immunotherapy (SCIT) prescribed within the German statutory health insurance].

Authors:  Christa Claes; Thomas Mittendorf; J-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-07-18

2.  A retrospective study of hyposensitization in canine atopy based on a polyclonal ELISA test.

Authors:  B K Saevik; S I Thoresen; F Kristensen
Journal:  Vet Res Commun       Date:  2002-12       Impact factor: 2.459

3.  Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic.

Authors:  Osman Ozan Yeğit; Semra Demir; Derya Ünal; Müge Olgaç; Kadriye Terzioğlu; Deniz Eyice Karabacak; Can Tüzer; Vehbi Ayhan; Bahattin Çolakoğlu; Suna Büyüköztürk; Aslı Gelincik
Journal:  Allergy       Date:  2021-05-10       Impact factor: 14.710

Review 4.  Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines.

Authors:  Omar Ali Aboshady; Karim Mohamed Elghanam
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-11-14       Impact factor: 3.372

5.  Adherence and systemic reaction rates to allergy immunotherapy among veterans.

Authors:  Joseph T Ellenburg; Jay A Lieberman; Debendra Pattanaik
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

6.  Patient's compliance with allergen immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Erminia Ridolo; Paola Puccinelli; Massimiliano Liuzzo; Silvia Scurati; Franco Frati
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

7.  Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol.

Authors:  Melina Makatsori; Gianenrico Senna; Constantinos Pitsios; Ramon Lleonart; Ludger Klimek; Carlos Nunes; Maia Rukhadze; Barbara Rogala; Radoslaw Gawlik; Petr Panzner; Oliver Pfaar; Moises Calderon
Journal:  Clin Transl Allergy       Date:  2015-04-27       Impact factor: 5.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.